Catalyst Wire Dossier Catalyst Wire Dossier
FDA label_change · 2025-02-25

FDA Approved: LEVETIRACETAM — Supplemental Application (Amneal Pharmaceuticals LLC)

View source ↗

Summary

The FDA approved a supplemental application for levetiracetam from Amneal Pharmaceuticals LLC, resulting in changes to the product labeling.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • LEVETIRACETAM (levetiracetam)

Snippet

SUPPL AP for LEVETIRACETAM (LEVETIRACETAM)